Clinical Trial

Semaglutide 2.4mg for Low Responders After Bariatric Surgery

Study acronym: SEABAR
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 1, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
In 20 - 30% of the patients, the low responders, sufficient weight loss is not achieved after bariatric surgery. Secondary and/or tertiary bariatric procedures can lead to successful weight loss and resolution of comorbid conditions though, morbidity and mortality rates of these procedures are high. Therefore, additional pharmacotherapy has been suggested. Semaglutide is one of the medications that might improve outcome in the post-bariatric population. Semaglutide is a Glucagon-like peptide-1 (GLP-1) receptor analogue developed to treat type 2 diabetes. It causes glucose-dependent insulin secretion, promotes satiety and inhibits glucagon secretion. In obese (non-bariatric) patients, semaglutide has shown to improve glycemic control, decrease blood pressure, lower cardiovascular risk, and decrease body weight.
Trial Details
NCT Number NCT06287307
Lead Sponsor Zuyderland Medisch Centrum
Collaborators: Nederlandse Obesitas Kliniek
Conditions Obesity, Obesity, Morbid, Weight Gain
Enrollment 152 participants
Start Date 2024-05
Primary Completion 2026-02 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2024-03-01